Perosphere Inc.
24 Old Wagon Road
Bedford
New York
10549
United States
Website: http://www.perosphere.com/
Email: Info@Perosphere.com
10 articles about Perosphere Inc.
-
Perosphere Technologies Awarded Federal Grants for Point-of-Care Coagulometer
9/19/2023
Perosphere Technologies has announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering.
-
With more than 15 million people in need of anticoagulants around the world, AMAG sees a significant future for ciraparantag.
-
Perosphere Pharmaceuticals' Ciraparantag Research Presented at American Society of Hematology Annual Meeting
12/4/2018
Findings from Studies Show that Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban
-
Perosphere Inc. Receives FDA Fast Track Designation For Investigational Anticoagulant Reversal Agent PER977
4/2/2015
-
Perosphere Inc.To Present Investigational Broad-Spectrum Anticoagulant Reversal Agent PER977 Data At American College of Cardiology 64th Annual Scientific Sessions
3/9/2015
-
Perosphere Inc.’s Anticoagulant Reversal Agent Clinical Trial Results Published In The New England Journal of Medicine
11/6/2014
-
Perosphere Inc. And Daiichi Sankyo, Inc. Enter Into A Clinical Trial Collaboration Agreement For Phase 3 Studies Of PER977 To Investigate Reversal Of The Anticoagulant Activity Of The Investigational Factor Xa-Inhibitor Edoxaban
10/6/2014
-
Perosphere Inc. Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation Therapies Including Factor Xa- and IIa-Inhibitors
5/22/2013
-
Perosphere Inc. and Daiichi Sankyo, Inc. Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
4/25/2013
-
Perosphere Inc. Launched -- First Close of $1.5 Million Series A Convertible Preferred Stock Offering
12/19/2011